Bambusa Therapeutics Closes Series A-2 for Bispecific Platform
17 Nov 2025 //
PR NEWSWIRE
Bambusa Therapeutics Reports Strong Healthy Volunteer Results
25 Sep 2025 //
PR NEWSWIRE
Bambusa Therapeutics: First Subject Dosed in BBT002 Phase 1 Trial
30 May 2025 //
PR NEWSWIRE
I&I Startup Bambusa Nabs $90M for Bispecific Antibodies
14 Feb 2025 //
BIOSPACE
Bambusa Therapeutics Secures Seed Funding For Bispecific Antibodies
09 Sep 2024 //
PR NEWSWIRE

Market Place
Sourcing Support